HIV-1-infection Clinical Trial
Official title:
Multicentre, Open-label, Post-approval Observational Study of Elpida® Used in the First Line Therapy for HIV-1 Infected Patients With the Background of Standard Baseline ART (NNRTI + 2 NRTIs)
This post-registration observational study is designed to monitor the safety parameters and efficacy of Elpida® in actual practice in the first-line treatment of HIV-1 infected patients on the background of the standard baseline ART.
This study is a multicenter, open-label, post-registration observational non-interventional
study of the use of Elpida® in the first line of therapy for HIV-1 infected patients against
a background of standard baseline ART (NNRTIs + 2 NRTIs). The study is scheduled to be
conducted approximately in 20 centers for the prevention and control of AIDS in Russia.
In total, 2000 HIV-1-infected patients who are prescribed therapy with Elpida® (20 mg
capsules) against the background of standard baseline ART are planned to be included in the
study.
The observational study will collect data from patients who signed informed consent and meet
all inclusion/non-inclusion criteria from the time that precedes the therapy by Elpida® up to
96 weeks of treatment or until early elimination. The data will be obtained through routine
visits and procedures, including demographics and history, height, body weight, body mass
index (BMI), laboratory data (viral load of HIV-1, CD4+-T-lymphocytes, resistance mutations
in HIV-1, screening for hepatitis B and C, syphilis, general and biochemical blood analysis,
general urine analysis) and instrumental examinations (electrocardiography (ECG), chest
X-ray/fluorography). Throughout the study, patients will keep observation diaries for
recording AEs and concomitant therapy. Data on the intake of ART drugs and AE related to
their use will also be collected.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03940521 -
Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
|
||
| Completed |
NCT03227731 -
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women
|
Phase 2/Phase 3 | |
| Completed |
NCT03570918 -
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04022967 -
ANRS 12372 MODERATO Study
|
Phase 3 | |
| Not yet recruiting |
NCT06337032 -
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
|
Phase 4 | |
| Not yet recruiting |
NCT06282783 -
Studying Topiramate for Re-Activating the HIV-1 Reservoir
|
Phase 1/Phase 2 | |
| Completed |
NCT04711265 -
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
|
||
| Recruiting |
NCT03536234 -
Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients
|
Phase 2 | |
| Completed |
NCT04340388 -
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
|
Phase 4 | |
| Withdrawn |
NCT05769569 -
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
|
Phase 1 | |
| Enrolling by invitation |
NCT05584397 -
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
|
||
| Completed |
NCT04963712 -
Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
|
Early Phase 1 | |
| Not yet recruiting |
NCT04894357 -
Impact of V106I on Resistance to Doravirine
|
||
| Completed |
NCT04388904 -
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
|
Phase 4 | |
| Completed |
NCT04568239 -
Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
|
||
| Not yet recruiting |
NCT04311944 -
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
|
N/A | |
| Not yet recruiting |
NCT04311957 -
Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults
|
Phase 4 | |
| Not yet recruiting |
NCT04513496 -
Telemedicine in HIV Care in Buenos Aires
|
||
| Completed |
NCT03998176 -
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
|
Phase 4 |